Federal contract award
75N94020F00001
2020.500-COVID-19 - BEST PHARMACEUTICALS FOR CHILDREN ACT PEDIATRIC TRIALS NETWORK - COVID-19 STUDIES
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NICHD |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 75N94018D00003 |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $7.4M |
| Current contract value | $7.4M |
| Potential contract value / ceiling | $7.4M |
| Start date | Sep 21, 2020 |
| Current end date | Jul 31, 2025 |
| Potential end date | Jul 31, 2025 |
| Latest award activity | Aug 27, 2024 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 4 of 4 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 27, 2024 | P00003 | $0 | 2020.500-COVID-19 - BEST PHARMACEUTICALS FOR CHILDREN ACT PEDIATRIC TRIALS NETWORK - COVID-19 STUDIES |
| Nov 16, 2023 | P00002 | $0 | 2020.500-COVID-19 - BEST PHARMACEUTICALS FOR CHILDREN ACT PEDIATRIC TRIALS NETWORK - COVID-19 STUDIES |
| Sep 28, 2022 | P00001 | $1000.0K | 2020.500-COVID-19 - BEST PHARMACEUTICALS FOR CHILDREN ACT PEDIATRIC TRIALS NETWORK - COVID-19 STUDIES |
| Sep 17, 2020 | 0 | $6.4M | 2020.500-COVID-19 - BEST PHARMACEUTICALS FOR CHILDREN ACT PEDIATRIC TRIALS NETWORK - COVID-19 STUDIES |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.